Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of transdermal SFG-02 in healthy adults
jRCT2071250058Phase 1Completed
- Sponsor
- Juro Sciences
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SFG-02 in None (6 arms), sponsored by Juro Sciences. Primary endpoints: Safety and tolerability and Pharmacokinetics of SFG-02. Started Aug 2025; status: completed.
02
Drugs
SFG-02
Beyond the preview
Go deeper on jRCT2071250058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250058.